title: Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
abstract: BACKGROUND
  Hepatocellular carcinoma (HCC) is the most common liver neoplasm and the fifth most common cancer worldwide. Intermediate stage HCC [traditionally defined as Barcelona Clinic Liver Cancer (BCLC) B disease and traditionally treated with trans arterial chemoembolization (TACE)] and advanced stage HCC (traditionally defined as BCLC C disease and traditionally treated with sorafenib) are two distinct disease entities with rapidly evolving multimodality treatment approaches. In this systematic review we explore the evidence surrounding the value of using a TACE/sorafenib combination in these two subsets of HCC.
  
  
  METHODS
  PubMed, Medline, the Cochrane Library, EMBASE and Google Scholar were searched using the terms "HCC" OR "Hepatoma" or "Liver cancer" AND "TACE" OR "Chemoembolization" AND "Sorafenib" and specifying only English literature. Outcomes of interest included time to progression and overall survival (TTP and OS), tumor response, and toxicities.
  
  
  RESULTS
  A total of 17 potentially relevant trials were identified, of which six studies were excluded. Hence, 11 trials involving 1,000 patients were included, encompassing two phase 1 studies, one phase 3 study, two retrospective analyses and six phase 2 studies. Median TTP was reported in five out of 11 studies and it ranged from 6.3 to 9.0 months. Median OS was reported in five out of 11 studies and it was similarly variable as PFS, ranging from 12 to 29 months. The DCR (disease control rate) was reported in eight out of 11 studies, ranging from 32 to 95%. Frequently reported grade 3/4 toxicities were increased aspartate transaminase/alanine transaminase, fatigue, hypertension, hand-foot skin reaction and diarrhea.
  
  
  CONCLUSIONS
  The sorafenib/TACE combination shows promise as an effective and tolerable treatment strategy for intermediate stage/advanced HCC. The reported efficacy of a sorafenib/TACE combination appears to compare favorably with sorafenib or TACE monotherapies, the most commonly implemented strategies for unresectable HCC. Further clinical studies are warranted to accurately determine which patients are expected to benefit most from such combination strategies.
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 11665, Egypt, omar.abdelrhman@med.asu.edu.eg.
authors.forename: O
authors.initials: O
authors.lastname: Abdel-Rahman
authors.forename: Z A
authors.initials: ZA
authors.lastname: Elsayed
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D016461:Chemoembolization, Therapeutic; D002986:Clinical Trials as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: World J Gastroenterol. 2008 Nov 14;14(42):6437-41
references.pmid: 19030192
references.citation: Oncologist. 2010;15(11):1198-204
references.pmid: 21036880
references.citation: Gut. 2002 Jun;50(6):881-5
references.pmid: 12010894
references.citation: World J Gastroenterol. 2004 Oct 1;10(19):2878-82
references.pmid: 15334691
references.citation: BMC Cancer. 2012 Jun 21;12:263
references.pmid: 22721173
references.citation: Eur Radiol. 2012 Jun;22(6):1214-23
references.pmid: 22215073
references.citation: Hepatology. 2003 Feb;37(2):429-42
references.pmid: 12540794
references.citation: Cancer Treat Rev. 2011 May;37(3):212-20
references.pmid: 20724077
references.citation: N Engl J Med. 1995 May 11;332(19):1256-61
references.pmid: 7708069
references.citation: Oncologist. 2012;17(3):359-66
references.pmid: 22334456
references.citation: Crit Rev Oncol Hematol. 2006 Nov;60(2):89-98
references.pmid: 16860993
references.citation: J Dig Dis. 2013 Apr;14(4):181-90
references.pmid: 23324079
references.citation: J Clin Oncol. 2011 Oct 20;29(30):3960-7
references.pmid: 21911714
references.citation: Cancer. 1985 Aug 15;56(4):918-28
references.pmid: 2990661
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Aliment Pharmacol Ther. 2011 Jul;34(2):205-13
references.pmid: 21605146
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Int J Cancer. 2013 May 15;132(10):2448-58
references.pmid: 23129123
references.citation: Eur J Cancer. 2011 Sep;47(14):2117-27
references.pmid: 21664811
references.citation: J Hepatol. 2012 Jun;56(6):1336-42
references.pmid: 22314421
references.citation: Ann Oncol. 2013 Jul;24(7):1786-1792
references.pmid: 23508822
references.citation: Transplant Proc. 2013 Jan-Feb;45(1):265-71
references.pmid: 23375313
references.citation: Acta Virol. 2012;56(3):235-40
references.pmid: 23043603
references.citation: J Hepatol. 1998 Jul;29(1):129-34
references.pmid: 9696501
references.citation: Hepatology. 2011 Mar;53(3):1020-2
references.pmid: 21374666